Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial.
Diez-Quevedo
Crisanto
C
Department of Psychiatry, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona, Ctra de Canyet s/n, 08916 Badalona, Spain. cdiezquevedo.germanstrias@gencat.cat
Masnou
Helena
H
Planas
Ramon
R
Castellví
Pere
P
Giménez
Dolors
D
Morillas
Rosa M
RM
Martín-Santos
Rocío
R
Navinés
Ricard
R
Solà
Ricard
R
Giner
Pilar
P
Ardèvol
Mercè
M
Costa
Joan
J
Diago
Moisés
M
Pretel
Juan
J
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015283:Citalopram / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000139:chemically induced* / Q000517:prevention & control; D004311:Double-Blind Method; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D015283:Citalopram; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a